share_log

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23

JP摩根保持对sage therapeutics的超配评级,将目标价格下调至23美元。
Benzinga ·  06/20 09:16

JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $28 to $23.

JP摩根分析师Anupam Rama认为Sage Therapeutics(纳斯达克:sage therapeutics)股票依然值得买进,但将目标价从28美元下调至23美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发